Drug
BEAM Regimen
BEAM Regimen is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(33%)
Phase Distribution
Ph phase_1
1
33%
Ph phase_2
1
33%
Ph phase_3
1
33%
Phase Distribution
1
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Other(1)
Detailed Status
Not yet recruiting1
Recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)
Trials by Status
not_yet_recruiting133%
recruiting133%
unknown133%
Recent Activity
1 active trials
Showing 3 of 3
not_yet_recruitingphase_2
Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive
NCT06652139
recruitingphase_3
A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
NCT05931263
unknownphase_1
Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis
NCT03113162
Clinical Trials (3)
Showing 3 of 3 trials
NCT06652139Phase 2
Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive
NCT05931263Phase 3
A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
NCT03113162Phase 1
Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3